Actinic (Solar) Keratosis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 73 pages report, published by Global Markets Direct

Keywords : Actinic (Solar) Keratosis Therapeutic Products under Development, Key Players in Actinic (Solar) Keratosis Therapeutics, Actinic (Solar) Keratosis Pipeline Overview, Actinic (Solar) Keratosis Pipeline, Actinic (Solar) Keratosis Pipeline Assessment

Report ThumbnailSeptember-2013
Actinic (Solar) Keratosis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Actinic (Solar) Keratosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Actinic (Solar) Keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis. Actinic (Solar) Keratosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Actinic (Solar) Keratosis.
- A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Actinic (Solar) Keratosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Actinic (Solar) Keratosis, H2 2013 9
  • Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Late Stage Products, H2 2013 13
  • Mid Clinical Stage Products, H2 2013 14
  • Early Clinical Stage Products, H2 2013 15
  • Discovery and Pre-Clinical Stage Products, H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 33
  • Assessment by Route of Administration, H2 2013 34
  • Assessment by Stage and Route of Administration, H2 2013 35
  • Assessment by Molecule Type, H2 2013 36
  • Assessment by Stage and Molecule Type, H2 2013 37
  • List of Tables
  • Number of Products Under Development for Actinic (Solar) Keratosis, H2 2013 9
  • Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Comparative Analysis by Late Stage Development, H2 2013 13
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
  • Products under Development by Companies, H2 2013 17
  • Galderma S.A., H2 2013 18
  • LEO Pharma A/S, H2 2013 19
  • Meda AB, H2 2013 20
  • NexMed, Inc., H2 2013 21
  • Clinuvel Pharmaceuticals Limited, H2 2013 22
  • Quest PharmaTech Inc., H2 2013 23
  • G&E Herbal Biotechnology Co., Ltd., H2 2013 24
  • Paloma Pharmaceuticals, Inc., H2 2013 25
  • Digna Biotech, S.L., H2 2013 26
  • Foamix Ltd., H2 2013 27
  • Telormedix SA, H2 2013 28
  • RIEMSER Arzneimittel AG, H2 2013 29
  • GENEXTRA S.p.A., H2 2013 30
  • Novelix Pharmaceuticals, Inc., H2 2013 31
  • Advancell, H2 2013 32
  • Assessment by Monotherapy Products, H2 2013 33
  • Assessment by Stage and Route of Administration, H2 2013 35
  • Assessment by Stage and Molecule Type, H2 2013 37
  • Actinic (Solar) Keratosis Therapeutics - Drug Profile Updates 60
  • Actinic (Solar) Keratosis Therapeutics - Discontinued Products 64
  • Actinic (Solar) Keratosis Therapeutics - Dormant Products 65
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Actinic (Solar) Keratosis Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Actinic (Solar) Keratosis 9
  • Actinic (Solar) Keratosis Therapeutics under Development by Companies 11
  • Late Stage Products 13
  • Comparative Analysis 13
  • Mid Clinical Stage Products 14
  • Comparative Analysis 14
  • Early Clinical Stage Products 15
  • Comparative Analysis 15
  • Discovery and Pre-Clinical Stage Products 16
  • Comparative Analysis 16
  • Actinic (Solar) Keratosis Therapeutics - Products under Development by Companies 17
  • Companies Involved in Actinic (Solar) Keratosis Therapeutics Development 18
  • Galderma S.A. 18
  • LEO Pharma A/S 19
  • Meda AB 20
  • NexMed, Inc. 21
  • Clinuvel Pharmaceuticals Limited 22
  • Quest PharmaTech Inc. 23
  • G&E Herbal Biotechnology Co., Ltd. 24
  • Paloma Pharmaceuticals, Inc. 25
  • Digna Biotech, S.L. 26
  • Foamix Ltd. 27
  • Telormedix SA 28
  • RIEMSER Arzneimittel AG 29
  • GENEXTRA S.p.A. 30
  • Novelix Pharmaceuticals, Inc. 31
  • Advancell 32
  • Actinic (Solar) Keratosis - Therapeutics Assessment 33
  • Assessment by Monotherapy Products 33
  • Assessment by Route of Administration 34
  • Assessment by Molecule Type 36
  • Drug Profiles 38
  • afamelanotide - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • TMX-202 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • P-529 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • SR-T-100 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • sotirimod - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • fluorouracil - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • SL-017 - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • resiquimod - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • ANs-40 - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • OxBue/OxHex - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • ingenol mebutate - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • AK-3012 - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • DAC-0060 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • NVX-207 - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • ANS-401 - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • ANS-403 - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • Drug For Actinic Keratosis - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • imiquimod - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • Actinic (Solar) Keratosis Therapeutics - Drug Profile Updates 60
  • Actinic (Solar) Keratosis Therapeutics - Discontinued Products 64
  • Actinic (Solar) Keratosis Therapeutics - Dormant Products 65
  • Actinic (Solar) Keratosis - Product Development Milestones 66
  • Featured News & Press Releases 66
  • Mar 20, 2013: Article Published In JAMA Dermatology Shows Long-term Effectiveness Of Leo Pharma's Ingenol Mebutate In Treating Actinic Keratosis 66
  • Mar 11, 2013: Moberg Derma Discontinues Clinical Development Of Limtop 67
  • Feb 19, 2013: Chugai Pharma Files Lawsuit On Patent Infringement Concerning Oxarol Ointment And Petition For Provisional Disposition Order 67
  • Jan 08, 2013: Biofrontera Receives Positive EMA Opinion On Extended Storage Conditions For Ameluz 67
  • Nov 19, 2012: LEO Pharma's Picato Gel Receives EU Marketing Authorization For Treatment Of Actinic Keratosis 68
  • Nov 05, 2012: Biofrontera Launches Ameluz In UK And Austria 69
  • Oct 15, 2012: Biofrontera And Bipharma Announce Launch Of Ameluz In Netherlands 70
  • Sep 20, 2012: Leo Pharma's Picato Obtains Positive Opinion From CHMP To Treat Actinic Keratosis In Adults 70
  • Sep 06, 2012: Moberg Derma Completes Recruitment For Phase II Study OF Limtop In Actinic Keratosis 71
  • Aug 13, 2012: Biofrontera Signs Distribution Agreement With Pelpharma For Marketing Of Ameluz In Austria 71
  • Appendix 72
  • Methodology 72
  • Coverage 72
  • Secondary Research 72
  • Primary Research 72
  • Expert Panel Validation 72
  • Contact Us 73
  • Disclaimer 73

Please select a license type

Share

Related Products

Global Markets DirectActinic (Solar) Keratosis - Pipeline Review, H2 2013Product ThumbnailActinic (Solar) Keratosis - Pipeline Review, H2 2013, Industry ReportProduct #: 113285
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved